Oncobiologics Inc (NASDAQ:ONS) was up 6.3% during mid-day trading on Tuesday . The stock traded as high as $1.02 and last traded at $1.02. Approximately 649,300 shares traded hands during trading, an increase of 1,245% from the average daily volume of 48,273 shares. The stock had previously closed at $0.96.
The company has a debt-to-equity ratio of -0.27, a current ratio of 0.41 and a quick ratio of 0.41.
Oncobiologics (NASDAQ:ONS) last released its quarterly earnings data on Tuesday, August 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $0.77 million for the quarter.
Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.
See Also: Hedge Funds Explained
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.